Van Nostrand Douglas, Wartofsky Leonard
Division of Nuclear Medicine, Washington Hospital Center, and Georgetown University Medical Center, Washington, DC 20010, USA.
Endocrinol Metab Clin North Am. 2007 Sep;36(3):807-22, vii-viii. doi: 10.1016/j.ecl.2007.04.006.
This article presents an overview of the use of radioactive iodine (131-I) in the treatment of patients who have well differentiated thyroid cancer. We review definitions; staging; the two-principal methods for selection of a dosage of 131-I for ablation and treatment; the objectives of ablation and treatment; the indications for ablation and treatment; the recommendations for the use of 131-I for ablation and treatment contained in the Guidelines of the American Thyroid Association, the European Consensus, the Society of Nuclear Medicine, and the European Association of Nuclear Medicine; the dosage recommendations and selection of dosage for 131-I by the these organizations; and the Washington Hospital Center approach.
本文概述了放射性碘(131-I)在分化型甲状腺癌患者治疗中的应用。我们回顾了定义、分期;选择131-I剂量进行消融和治疗的两种主要方法;消融和治疗的目标;消融和治疗的适应症;美国甲状腺协会、欧洲共识、核医学协会和欧洲核医学协会指南中关于使用131-I进行消融和治疗的建议;这些组织对131-I的剂量建议和剂量选择;以及华盛顿医院中心的方法。